Lifecore Biomedical to Participate at 12th Annual American Biomanufacturing Summit
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) will participate at the 12th Annual American Biomanufacturing Summit on April 14-15, 2026 in San Francisco. Lifecore will discuss process development and manufacturing services for injectable programs and staff will be available at Booth 41.
Investors and partners may request meetings via cdmo@lifecore.com.
Positive
- None.
Negative
- None.
News Market Reaction – LFCR
In the Apr 8 session, LFCR gained 3.16%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.8% during that session. Our momentum scanner triggered 28 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Inducement equity grant | Neutral | -5.4% | Inducement RSU award of 18,500 shares to a new employee. |
| Mar 26 | CDMO agreements | Positive | -7.6% | Two new CDMO manufacturing agreements adding to late-stage pipeline. |
| Mar 23 | Site transfer deal | Positive | +0.8% | Commercial site transfer for an aesthetic sterile product with revenue potential. |
| Mar 16 | Earnings and update | Positive | -24.4% | Revenue growth, margin expansion, and 2026 guidance with higher EBITDA. |
| Mar 10 | Conference participation | Neutral | -1.3% | Participation in KeyBanc healthcare forum and investor meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates have often been followed by negative price reactions, while neutral conference-type news has not driven consistent gains.
Over the past months, Lifecore reported stronger fundamentals, including Q4 and transition-period revenue of $35.7M and $75.5M with improved 31.4% margins and $13.1M Adjusted EBITDA, yet the stock fell 24.39% after that update. The company has signed multiple CDMO site transfer and manufacturing agreements expected to support commercial revenue and a targeted 12% 2029 revenue CAGR, but those announcements also saw negative short-term reactions. Prior conference participation on Mar 17–18, 2026 corresponded to only a small move. Today’s biomanufacturing summit participation fits this pattern of neutral visibility events.
Key Terms
cdmo technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA.
Details regarding Lifecore’s participation are as follows:
- 12th Annual American Biomanufacturing Summit
Details: Lifecore team will be present to discuss process development and manufacturing services for injectables programs.
Booth number: 41
Conference Dates: April 14 - 15, 2026
Location: Hyatt Regency San Francisco Airport, San Francisco, CA
If you are interested in meeting with Lifecore during this event, please reach out to us at: cdmo@lifecore.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com\
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com
